We know you don’t have time to read it all. Here are some of the studies that caught our eye this week.
|Desipramine as a Treatment for OAB
Patients with overactive bladder (OAB) who are refractory to first-line anticholinergic agents such as oxybutynin may need to be prescribed tricyclic antidepressants (eg, imipramine, amitriptyline) to treat their OAB. In this study, researchers evaluated the use of desipramine, a metabolite of imipramine, to see whether the drug would work in reducing the symptoms of OAB. Study results indicate that desipramine could potentially be an effective treatment for OAB with the added benefit of having fewer CNS side effects than other tricyclic antidepressants.
Original source: Urology Journal
|Are Obese Patients Being Rejected from the Wait-List?
In most transplant centers, one criterion that is used to determine whether a patient is eligible to be wait-listed for a kidney transplant is their body mass index (BMI). While there are concerns that obese recipients may have worse outcomes post-transplant than patients with normal BMI, the authors believe the concern is not great enough to deny these patients the right to be wait-listed. The authors question whether ulterior motives may be at play when transplant centers evaluate obese patients for kidney transplant.
Original Source: Seminars in Dialysis
|An Overview of Peyronie’s Disease Treatment
In this article, recent data is presented discussing the use of intralesional collagenase for the treatment of Peyronie’s disease, a curvature deformity of the penis due to the presence of a plaque. Based on current guidelines, there is no grade A evidence for the use of drugs such as steroids, verapamil or interferon in the intralesional treatment of Peyronie’s disease. Oral therapies, such as colchicine and tamoxifen, have also not shown any benefit in reducing deformity. Xiaflex (collagenase clostridium histolyticum; Auxillium) is the first FDA-approved non-surgical treatment for men with this condition. The article provides a review of the literature and clinical trial data on the use of intralesional pharmacotherapy.
Original Source: Therapeutic Advances in Urology